Wedbush lowered the firm’s price target on MannKind (MNKD) to $8 from $10 and keeps an Outperform rating on the shares. Last week’s Q4 update, despite strong revenue across all commercial assets and guidance on increased investments in 2026, did not fully address investors’ concerns caused by a novel soft mist inhaler of that partner United Therapeutics (UTHR) announced for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, the firm notes.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
- MannKind price target lowered to $7 from $8 at Wells Fargo
- MannKind price target lowered to $8 from $11 at H.C. Wainwright
- MannKind downgraded to Sector Perform from Outperform at RBC Capital
- MannKind reports Q4 EPS (5c) vs 3c last year